| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42d5a7b8d59ab5359cbc8a055bdb44d0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-102 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39533
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2015-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_659dbd6be768e867a26982764eac0d08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4277f086814f51ee4cf4680fcd35c23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f544db9933c6f3f11748c6d327fef301
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_274d0da0245e9251aa6ec5756494dd2b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1cca14f65b4423fd346277d625aa8d18 |
| publicationDate |
2017-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20170071680-A |
| titleOfInvention |
Antibodies Capable of Binding Specifically to CD80 and CD86 |
| abstract |
The present invention relates to novel antibodies to CD80 and CD86 used in the prevention or treatment of rheumatoid arthritis. The antibody of the present invention is an antibody that specifically binds CD80 and / or CD86 that is overexpressed in a cell. The antibodies of the present invention have homology to the sequences because they have very low homology compared to the CDR sequences of conventional CD80 and / or CD86 target antibodies. The antibody of the present invention has the ability to inhibit T cell activity equivalent to that of avatacept used in the treatment of rheumatoid arthritis in a single treatment and has remarkably superior ability to inhibit T cell activity than the avatacept when the CD80 target antibody and the CD86 target antibody are used in combination And is very effective in the prevention or treatment of rheumatoid arthritis. |
| priorityDate |
2015-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |